Phase 3 Clinical Trials With Primary Completion Dates in September 2019
This is a list of Phase 3 trials with primary completion dates in September 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals, Inc. | 2019-09-01 | Phase 3 | NCT03436199 | Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment |
| CCXI | ChemoCentryx, Inc. | 2019-09-01 | Phase 3 | NCT02994927 | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis |
| CPRX | Catalyst Pharmaceuticals, Inc. | 2019-09-01 | Phase 3 | NCT02562066 | Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes |
| CVM | Cel-Sci Corporation | 2019-09-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| FGEN | FibroGen, Inc | 2019-09-01 | Phase 3 | NCT02988973 | A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia |
| KALA | Kala Pharmaceuticals, Inc. | 2019-09-01 | Phase 3 | NCT03616899 | Safety and Efficacy of KPI-121 in Subjects With DED |
| LNTH | Lantheus Holdings, Inc. | 2019-09-01 | Phase 3 | NCT03719612 | DEF-315 Better Accuracy in EF Assessment With DEFINITY |
| LNTH | Lantheus Holdings, Inc. | 2019-09-01 | Phase 3 | NCT03571672 | DEF-314 Better Accuracy in EF Assessment With DEFINITY |
| OBSV | ObsEva SA | 2019-09-01 | Phase 3 | NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
| PEN | Penumbra, Inc. | 2019-09-01 | Phase 3 | NCT02216643 | EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke |
| SCYX | SCYNEXIS, Inc. | 2019-09-01 | Phase 3 | NCT03059992 | Open-Label Study to Evaluate Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Refractory or Intolerant Fungal Diseases |
| SYNH | Syneos Health, Inc. | 2019-09-01 | Phase 3 | NCT03719612 | DEF-315 Better Accuracy in EF Assessment With DEFINITY |
| SYNH | Syneos Health, Inc. | 2019-09-01 | Phase 3 | NCT03571672 | DEF-314 Better Accuracy in EF Assessment With DEFINITY |
| SYNH | Syneos Health, Inc. | 2019-09-01 | Phase 3 | NCT03023540 | Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A |
| TEVA | Teva Pharmaceutical Industries Limited | 2019-09-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 2019-09-01 | Phase 3 | NCT03508700 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD |